6572.TWO PlexBio Co., Ltd.
- Market cap
- TWD 630M
- P/E
- -
- P/B
- 2.09x
- ROE
- -20.1%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2025.
Is 6572.TWO undervalued?
Graham numberThe Graham number of PlexBio Co., Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
PlexBio Co., Ltd. fundamental analysis
No fundamental analysis for PlexBio Co., Ltd. yet.
PlexBio Co., Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It provides workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and customized pCode assays. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
Full company profilePlexBio Co., Ltd. financial statements
PlexBio Co., Ltd. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 101M | 125M | 191M | 167M | 128M | 127M |
| Gross Profit | - | 41.7M | 38.6M | 59.0M | 62.5M | 49.3M | 40.4M |
| Operating Income | - | -148M | -135M | -66.9M | -64.2M | -79.5M | -65.6M |
| EBITDA | -149M | -116M | -107M | -32.9M | -40.3M | -42.7M | -45.7M |
| Net Income | - | -141M | -132M | -53.1M | -58.5M | -61.6M | -62.5M |
| EPS | - | -1.37 | -1.27 | -0.51 | -0.56 | -0.59 | -0.60 |
| Balance Sheet | |||||||
| Total Assets | - | 823M | 733M | 582M | 517M | 572M | 447M |
| Total Liabilities | - | 161M | 198M | 103M | 92.3M | 198M | 136M |
| Shareholders' Equity | - | 662M | 534M | 479M | 424M | 374M | 310M |
| Cash & Short-term Investments | - | 666M | 562M | 479M | 428M | 416M | 191M |
| Total Debt | 494K | 9.49M | 9.15M | 6.02M | 10.9M | 5.67M | - |
| Cash Flow | |||||||
| Operating Cash Flow | - | -111M | -84.3M | -71.4M | -29.3M | -5.06M | -79.1M |
| Capital Expenditure | 0.00 | 6.49M | 11.6M | 2.02M | 3.07M | 3.59M | 413K |
| Free Cash Flow | - | -117M | -95.9M | -73.5M | -32.3M | -8.64M | -79.5M |
| Ratios | |||||||
| ROE | - | -21.3% | -24.6% | -11.1% | -13.8% | -16.5% | -20.1% |
| ROA | - | -17.1% | -18.0% | -9.1% | -11.3% | -10.8% | -14.0% |
| Net Profit Margin | - | -139.2% | -105.3% | -27.8% | -35.0% | -48.1% | -49.2% |
| Debt to Equity | - | 0.01x | 0.02x | 0.01x | 0.03x | 0.02x | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
PlexBio Co., Ltd. dividends
PlexBio Co., Ltd. has not paid dividends in the last 7 fiscal years.
Who owns PlexBio Co., Ltd.
Ownership data of PlexBio Co., Ltd. is not available yet.
PlexBio Co., Ltd. company profile
- Company name
- PlexBio Co., Ltd.
- Ticker
- 6572.TWO
- ISIN
- TW0006572001
- Exchange
- Taiwan OTC Exchange
- Sector
- Healthcare
- Industry
- Medical Devices
- Fiscal year end
- December
- Address
- No. 351, Yangguang Street, Taipei, Taiwan, 11491
- Phone
- 886 2 2627 5878
- Website
- plexbio.com
About PlexBio Co., Ltd.
PlexBio Co., Ltd. develops and manufactures in vitro diagnostic reagents for molecular biology and immunology projects. It provides workflow navigation services; automated sample preparation kits; IntelliPlex platform that is designed for pCode technology with throughput sample-to-answer multiplexing assays; oncology assays, a portfolio for advanced molecular testing; and customized pCode assays. PlexBio Co., Ltd. was founded in 2009 and is based in Taipei, Taiwan.
PlexBio Co., Ltd. management
6- Dr. Ting Cao Ph.D.Chairman, President & CEO
- Ms. Lipi YehChief Financial Officer
- Jiahong HongAccounting Supervisor
- Dr. Chin-Shiou HuangVP & CTO
- Mr. Huei Te UweSenior Administration Manager
- Dr. Jason LeiSenior Vice President of Research & Development